Mar 9, 2017 Cellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance Learn More
Mar 8, 2017 Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement Learn More
Feb 27, 2017 Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months Learn More